MarketMoodz
Genmab/AbbVie Lymphoma Trial Shows PFS Win; Upside Ahead
Benzinga reports that the Phase 3 EPCORE DLBCL-4 trial of epcoritamab (Tecvayli) plus lenalidomide met its primary endpoint, showing improved progression-free survival versus standard-of-care R‑GemOx in relapsed/refractory DLBCL. If confirmed by a company press release or conference presentation, the data could open a path to label expansion and materially enlarge the addressable market for Genmab and AbbVie.
Key Takeaways
- EPCORE DLBCL-4 topline (per Benzinga) met the primary endpoint with a PFS improvement for epcoritamab plus lenalidomide versus R‑GemOx in relapsed/refractory DLBCL.
- Reported hazard ratios: 0.40 with U.S. censoring and 0.44 outside the U.S., implying roughly a 56–60% reduction in risk of progression or death.
- Safety for the combo was described as consistent with the known profiles of epcoritamab and lenalidomide, pending full safety data.
- William Blair analyst Matt Phipps projects potential label expansion to second-line-plus DLBCL (~21,000 patients) and a frontline EPCORE DLBCL-2 readout in 2026 (~70,000 patients).
- Analyst scenarios envision up to $8 billion in combined peak sales across Darzalex, Kesimpta and Tecvayli, though regulatory, payer and competitive dynamics are key caveats.
People Involved
- Matt PhippsWilliam Blair analyst
Entities Involved
- Genmab (GMAB)Co-developer of epcoritamab (Tecvayli)
- AbbVie (ABBV)Co-developer and commercial partner for epcoritamab
- William BlairInvestment bank providing analyst projections
- BenzingaNews outlet reporting the topline results
- EPCORE DLBCL-4 (Phase 3 trial)Trial comparing fixed-duration epcoritamab + lenalidomide vs R‑GemOx in relapsed/refractory DLBCL
- R-GemOxComparator regimen (rituximab + gemcitabine + oxaliplatin)
MarketMoodz Analysis
If the reported PFS win holds up under full data release and regulatory scrutiny, investors should view this as a tangible step toward expanding Tecvayli’s label beyond later-line settings. The reported hazard ratios (0.40 U.S.; 0.44 non-U.S.) indicate a large relative benefit in delaying progression or death—roughly a 56–60% reduction in risk—but topline figures don’t show the full picture. Key drivers for commercial impact will be durability of benefit (overall survival and median PFS), detailed safety data, and whether the fixed-duration, potentially outpatient administration can displace longer or more complex regimens in routine practice.
Context matters: the hematology market is crowded with CD20-directed antibodies, CAR-T therapies and other bispecifics competing for DLBCL patients. William Blair’s projection of a second-line-plus pool near 21,000 patients and a 2026 frontline readout targeting ~70,000 patients offers a clear path to material revenue upside—hence the analyst’s up-to-$8 billion peak-sales scenario across Darzalex, Kesimpta and Tecvayli. That upside is conditional: regulators must accept the data, payers must grant access (pricing and real-world effectiveness will matter), and Genmab/AbbVie will need to fend off rivals. Near term, watch for the official press release or conference slides, detailed PFS and safety curves, any regulatory timelines, and subsequent market reactions for GMAB and ABBV stock and valuation multiples.
Source: Original Article